Anthera Pharmaceuticals Overview
- Founded
-
2004
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
ANTH
- Investments
-
1
Anthera Pharmaceuticals General Information
Description
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 25801 Industrial Boulevard
- Suite B
- Hayward, CA 94545
- United States
+1 (510) 000-0000
Anthera Pharmaceuticals Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 15.2K |
Anthera Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2018 | FY 2017 31-Dec-2017 | FY 2016 31-Dec-2016 | FY 2015 31-Dec-2015 |
|---|---|---|---|---|
| EV | 5,610 | 17,109 | (1,648) | 129,260 |
| Revenue | 0 | 0 | 145 | 3,185 |
| EBITDA | (22,994) | (26,593) | (55,257) | (34,935) |
| Net Income | (23,391) | (26,874) | (55,523) | (35,220) |
| Total Assets | 8,811 | 3,673 | 23,471 | 48,125 |
| Total Debt | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Anthera Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Anthera Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Anthera Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to tr
Biotechnology
Hayward, CA
21
As of 2017
00000
00000000
00000
00000
um dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
000000000000000
Durham, NC
000
As of 0000
00000
000000 - 000
00000
000000
in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat n
0000000000000
San Diego, CA
00
As of 0000
000.00
0000
0000-00-00
000000&0
000.00
Add Comparison
Anthera Pharmaceuticals Competitors (50)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aerie Pharmaceuticals | Formerly VC-backed | Durham, NC | 000 | 00000 | 000000 - 000 | 00000 |
| 000000 | Formerly VC-backed | San Diego, CA | 00 | 000.00 | 000000&0 | 000.00 |
| 000000 000000 0000 | Formerly VC-backed | Seattle, WA | 00 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Corporation | Basking Ridge, NJ | 00 | 00000 | 000000&0 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000&0 | 00000 |
Anthera Pharmaceuticals Patents
Anthera Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170369551-A1 | Methods of treating iga nephropathy and henoch-schonlein purpura nephritis using a b-cell activating factor (baff) inhibitor | Abandoned | 24-Jun-2016 | 000000000000 | |
| US-20110301202-A1 | Spla2 inhibitor conjugate compounds and methods of use | Abandoned | 04-Jun-2010 | 00000000000 | |
| US-20110269786-A1 | Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies | Abandoned | 30-Apr-2010 | 0000000000 | |
| CA-2749534-A1 | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | Abandoned | 08-Jan-2009 | 000000000 | |
| US-20100204249-A1 | Secretory phospholipase a2 (spla2) inhibitor and niacin drug compositions and methods for treating cardiovascular disease and dyslipidemia | Abandoned | 08-Jan-2009 | A61K45/06 | 0 |
Anthera Pharmaceuticals Executive Team (13)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| John Thompson | Chief Executive Officer & Board Member | ||
| Charles Olson | Chief Technology Officer | ||
| May Liu | Chief Accounting Officer, Accounting & Senior Vice President |
Anthera Pharmaceuticals Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Brent Furse | Self | Board Member | 000 0000 |
| Brian Mueller | Self | Board Member | 000 0000 |
| Christopher Henney Ph.D | Self | Board Member | 000 0000 |
| David Thompson | Self | Board Member | 000 0000 |
| John Thompson | Anthera Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
Anthera Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Anthera Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Anthera Pharmaceuticals Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 00000 000 | 14-Jul-2014 | 000000000 | Buildings and Property | 0000 0000 |